The Use of Epoetin Alfa and Iron Derisomaltose in the Treatment of Anemia in Patients With Sepsis or Septic Shock Hospitalized in the Intensive Care Unit: a Randomized Controlled Clinical Trial

Background Up to 66% of ICU patients have anemia when admitted. This number increases to 95% after 72 hours due to illness and frequent blood tests. Anemia worsens the risk of tissue oxygen shortage, especially for those with sepsis or septic shock, who already have blood flow issues. Instead of giving blood transfusions, which can have side effects, we aim to address the root causes of anemia in these patients. Sepsis can cause "inflammatory anemia" and combine with iron deficiency anemia. Current treatments involve drugs to stimulate red blood cell production and intravenous iron supplements. Some think that iron supplements can worsen infections by feeding pathogens, but this is not conclusively proven. Since transfused red blood cells (RBC) also contain iron, small doses of intravenous iron might help sepsis patients with iron deficiency.
There is a need for a study on the effects of epoetin alfa and iron derisomaltose on hemoglobin (Hb) levels in sepsis patients.
Hypothesis and Aim Treating anemia in sepsis patients could increase Hb levels and reduce RBC transfusions, improving treatment outcomes. This study aims to evaluate the effects of epoetin alfa ± iron derisomaltose on Hb levels and RBC transfusion rates.
Primary Endpoints:
1. Hb difference at study exit (discharge from ICU/death/bleeding/need for surgery/day 15 whatever comes first) and day 1 corrected for Hb increase due to possible RBC transfusion
Secondary Endpoints:
1. Hb difference on days 8 and 1 corrected for Hb increase due to possible RBC transfusion
2. Hb difference on days 15 and 1 corrected for Hb increase due to possible RBC transfusion
3. number of blood transfusions
4. percentage of patients receiving at least one blood transfusion
5. actual vs. predicted mortality, prevalence of deep vein thrombosis and pulmonary embolism
6. mortality rates in ICU, hospital, 30-day, and 90-day.
Materials and Methods:
This will be a randomized controlled clinical trial with 200 patients
Inclusion Criteria:
1. age ≥18
2. diagnosed sepsis (Sepsis-3 definition) or septic shock (Septic Shock-3 definition)
3. hemoglobin <120 g/L for both sexes
Exclusion Criteria:
1. bleeding
2. decompensated liver disease
3. inherited microcytic disorders
4. macrocytosis
5. contraindications to pharmacological prophylaxis for venous thromboembolism
6. pregnancy
7. allergy to epoetin alfa and/or iron derisomaltose.
8. ferritin >800 ng/mL.
9. inability to take consent
Study Group:
1. epoetin alfa 50 u/kg IV (days 1, 3, 5, 8, 10, 12)
2. iron derisomaltose 0.2g IV when RET-He <29.3 pg (days 1, 3, 5, 8, 10, 12)
3. algorithm for red blood cell transfusions
Control Group:
Standard care: algorithm for red blood cell transfusions
Laboratory Parameters:
Initial: interleukin-6, C-reactive protein, procalcitonin, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.
Serial: CBC and RET (days 1, 3, 5, 8, 10, 12)

开始日期2024-11-10

申办/合作机构

Medical University of Silesia

NCT05451940 / Active, not recruiting临床1/2期IIT

Assessing Combination Hydroxyurea and Exogenous Erythropoietin in Sickle Cell Disease

The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).

开始日期2023-05-25

申办/合作机构

University of Pittsburgh

[+2]

TCTR20230117005 / Recruiting临床4期IIT

Recombinant human erythropoietin increasing hemoglobin level and reducing blood transfusion in femoral fracture patients, a randomized controlled trial study

开始日期2022-07-29

申办/合作机构-

100 项与促红素α 相关的临床结果

登录后查看更多信息

100 项与促红素α 相关的转化医学

登录后查看更多信息

100 项与促红素α 相关的专利（医药）

登录后查看更多信息

1,388

项与促红素α 相关的文献（医药）

2024-12-01·Chronic diseases and translational medicine

Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial

[This corrects the article DOI: 10.1002/cdt3.23.].

2024-10-27·Cureus Journal of Medical Science

Efficacy of Epoetin Alfa in Managing Symptomatic Anaemia in Low-Risk Myelodysplastic Syndromes: A Retrospective Analysis

Article

作者: Aboulela, Mohamed ; Collins, Angela

Background Myelodysplastic syndromes (MDS) are clonal myeloid disorders characterised by ineffective haematopoiesis, leading to anaemia that often requires dependence on red blood cell (RBC) transfusions. Epoetin alfa (Eprex®) is now a mainstay in the management of symptomatic anaemia in low-risk MDS patients, reducing transfusion dependence and improving the quality of life in this patient group. Objective This retrospective study aimed to assess the efficacy of epoetin alfa in treating symptomatic anaemia in low-risk MDS patients, focusing on transfusion independence and its relationship with baseline erythropoietin (EPO) levels and haemoglobin (Hb) response. Methods Data from 56 patients with low-risk MDS treated with epoetin alfa at Norfolk and Norwich University Hospital, Norwich, United Kingdom, between 2018 and 2023 were retrospectively analysed. Baseline EPO levels, transfusion history, Hb response, and the duration of transfusion independence were assessed. Statistical analyses were performed to evaluate the correlation between baseline characteristics and treatment outcomes. Results Among the patients, 98.2% had baseline EPO levels below the 500 IU/L threshold, with a median EPO level of 74.3 IU/L. Following an eight-week trial of 30,000 units of epoetin-alfa, 41.1% of patients showed improved Hb levels, 41.1% maintained stable Hb levels, and 17.9% experienced a decline. A significant correlation was found between lower baseline EPO levels (<250 IU/L) and a positive treatment response (p = 0.0065). Additionally, patients who required fewer transfusions before treatment had longer durations of transfusion independence (correlation coefficient = -0.40, p = 0.015). Dose escalation to 60,000 units provided a benefit to 53.3% of patients with initially stable Hb levels. The average duration of transfusion independence was 8.1 months, and patients with improved Hb levels had the longest periods of transfusion independence (p = 0.005). Conclusion Epoetin alfa is an effective therapy for managing symptomatic anaemia in low-risk MDS patients. This study highlights its efficacy and provides valuable predictive information, particularly showing that patients with lower baseline EPO levels are more likely to respond to treatment. While prior transfusion dependence did not significantly predict response to therapy in this cohort, it was associated with the duration of transfusion independence.

2024-09-24·Polish Archives of Internal Medicine-Polskie Archiwum Medycyny Wewnetrznej

Initial experiences with combined therapy of anemia with roxadustat and epoetin α in hemodialysis patients: a case series

Article

作者: Dębska‑Ślizień, Alicja ; Biedunkiewicz, Bogdan ; Tylicki, Leszek ; Dębska-Ślizień, Alicja ; Jankowska, Magdalena ; Komorniczak, Michał

121

项与促红素α 相关的新闻（医药）

2024-12-12

·GlobeNewswire-Health Care

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited to welcome Eric Benevich to the Board of Directors,” said Timothy P. Coughlin, Chairman of the Board of aTyr. “His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization.” Mr. Benevich has served as Chief Commercial Officer of Neurocrine since May 2015 and is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine product portfolio. Mr. Benevich has over 30 years of commercial experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals in the sales and marketing of drugs such as Prilosec®, Epogen®, Enbrel®, and Neudexta®. Mr. Benevich has a BBA in International Business from Washington State University. About aTyr aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential benefits that Mr. Benevich’s appointment will have on aTyr’s evolution towards commercialization. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contact:Ashlee DunstonDirector, Investor Relations and Corporate Communicationsadunston@atyrpharma.com

高管变更

2024-11-26

·ioncology

2024 ASH重磅丨六项LBA摘要公布，一文了解血液学最前沿

编者按第66届美国血液学会（ASH）年会将于2024年12月7～10日在美国圣迭戈（San Diego）盛大召开。作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一，每年吸引着成千上万名来自世界各地的专家学者，分享最前沿的血液学进展和突破性临床数据。当地时间11月25日，大会官网公布了本次入选的最新重磅摘要（Late-Breaking Abstracts，LBA）共6项，将由研究者于当地时间2024年12月10日上午7:30至9:00，在会议现场Hall B (San Diego Convention Center)进行报告。本刊第一时间整理这6项LBA的核心要点，供大家提前阅览。 01 LBA-1 标题：Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND) 中文标题：坦昔妥单抗联合来那度胺和利妥昔单抗治疗复发或难治性滤泡性淋巴瘤：III期研究（inMIND）结果汇报人：Laurie H. Sehn（BC癌症中心淋巴瘤中心，加拿大）研究结论在来那度胺和利妥昔单抗的基础上加用坦昔妥单抗，显著且有临床意义地改善了无进展生存期（PFS），使复发/难治性滤泡性淋巴瘤（R/R FL）患者的疾病进展、复发或死亡风险降低了57%。尽管总生存期（OS）数据尚不成熟，但观察到了一种有利于塔坦昔妥单抗的趋势。其安全性特征可控，且与预期毒性一致。本研究首次验证了将两种单克隆抗体（抗CD19与抗CD20）联合用于淋巴瘤治疗的有效性。坦昔妥单抗+来那度胺+利妥昔单抗既可在社区环境中使用，也可在学术环境中使用，是R/R FL患者潜在的新标准治疗选择。 02 LBA-2 标题：Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis 中文标题：识别具有增强活性的肝样促红细胞生成素作为遗传性和获得性红细胞增多症的新原因汇报人：Betty Gardie[巴黎高等研究实践学院（EPHE），法国] 研究结论本研究报告了一种名为肝样促红细胞生成素增多症（HEP）的新型继发性红细胞增多症，其特征是产生具有非典型糖基化模式和活性增强的肝样促红细胞生成素（EPO）。这种新型EPO在所有遗传性EPO突变型红细胞增多症患者、与肝病相关的红细胞增多症病例以及新生儿中均有观察到。有趣的是，新生儿体内从更活跃的肝型EPO向肾型EPO的转变，可能解释了生命最初几周内血红蛋白水平显著下降的典型现象。因此，在进行特发性和遗传性红细胞增多症的诊断时，将定量和定性EPO筛查作为生物学检查的一部分是至关重要的。 03 LBA-3 标题：Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence 中文标题：比较减剂量与全剂量直接口服抗凝药延长治疗高风险复发静脉血栓栓塞症 Francis Couturaud（布雷斯特大学、FCRIN INNOVTE网络，法国）研究结论在需要延长抗凝治疗的静脉血栓栓塞症患者中，尚无法证明使用减剂量与全剂量直接抗凝药物在预防静脉血栓栓塞症复发方面的非劣效性。在减剂量组，临床相关出血以及静脉血栓栓塞症复发或临床相关出血的复合终点发生率均低于全剂量组，且这一优势并未因死亡或动脉血栓栓塞事件风险增加而抵消。 04 LBA-4 标题：Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) 中文标题：富含安第斯特征的NFKB1单倍型可降低真性红细胞增多症（PV）和原发性血小板增多症（ET）患者的炎症水平，并提高对罗培干扰素α-2b的应答率汇报人：Jihyun Song（亨斯迈癌症研究所，美国）研究结论本研究显示，与NFKB1野生型等位基因相比，富含艾马拉族特征的NFKB1 rs230511单倍型可降低真性红细胞增多症（PV）和原发性血小板增多症（ET）患者的炎症、促血栓形成及缺氧诱导因子（HIF）活性。此外，NFKB1 rs230511单倍型还能调节PV和ET患者对罗培干扰素的应答。携带NFKB1 rs230511 T等位基因的患者，其炎症和HIF靶向基因的表达降低，这可能潜在地减少PV和ET患者的炎症和血栓形成风险。携带C/T基因型的患者更有可能实现完全血液学缓解（CHR），这表明这种NFKB1单倍型可能影响罗培干扰素的治疗效果，并可作为评估PV和ET患者治疗应答的潜在生物标志物。这些新的见解对我们理解炎症和促血栓形成过程具有重要意义，并可能为PV和ET的新型疗法提供线索。 05 LBA-5 标题：Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities 中文标题：Drepagreffe试验中接受异体干细胞移植与标准治疗的镰状细胞贫血症伴异常脑血流速度病史患儿的10年脑血管病变情况及认知功能结局比较汇报人：Françoise Bernaudin（巴黎东部大学，法国）研究结论这项首个前瞻性比较试验表明，异体干细胞移植（alloSCT）与标准治疗（SoC）之间的差异在10年后发生了显著变化，其中异体干细胞移植在无症状性脑梗死（SCI)方面提供了更好的一级预防效果，同时改善了患者的社会生活质量、工作记忆和处理速度。 06 LBA-6 标题：Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial 中文标题：自体造血干细胞移植（auto-HCT）对首次完全缓解（CR）且无法检测到微小残留病（uMRD）的套细胞淋巴瘤（MCL）患者（pts）无益处：ECOG-ACRIN EA4151 III期随机试验的初步报告汇报人：Timothy S. Fenske（威斯康星医学院，美国）研究结论本次中期分析显示，在高效诱导和维持治疗方案时代，首次完全缓解（CR）且无法检测到微小残留病（uMRD）的套细胞淋巴瘤（MCL）患者并未从巩固性自体造血干细胞移植（auto-HCT）中获益。而诱导治疗后MRD仍为阳性的患者可能从auto-HCT中获益。更长时间的随访对于证实这些发现至关重要。（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床结果

2024-11-18

·PRNewswire

Fresenius Medical Care's AI-Powered Application of the Anemia Control Model Selected for CMS AI Demo Days in the United States

Fresenius Medical Care's application of the Anemia Control Model recognized as one of only six projects chosen from over 300 submissions across all healthcare segments. This selection highlights Fresenius Medical Care's commitment to improving kidney care and outcomes through innovative analytics and clinical expertise. Anemia Control Model, currently in use in clinics outside the United States, applies advanced AI technology to optimize anemia management in people with kidney disease and address challenges with erythropoietin and iron therapies. BAD HOMBURG, Germany, Nov. 18, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, and its subsidiary, the Renal Research Institute (RRI), announced that their application of the Anemia Control Model (ACM) was featured at the first Centers for Medicare & Medicaid Services (CMS) artificial intelligence (AI) Demo Days in the U.S. The model leverages advanced AI to support nephrologists in optimizing anemia management for people with end-stage renal disease (ESRD). "Being selected for CMS AI Demo Days reflects our commitment to improving the lives of people with kidney disease through practical and usable advanced, data-driven solutions," said Frank Maddux, MD, Global Chief Medical Officer and member of management board at Fresenius Medical Care AG. "The Anemia Control Model embodies our dedication to providing nephrologists with meaningful insights that enhance care for people with advanced kidney-related anemia, improving outcomes and their quality of life." The ACM is designed to recommend optimal dosages of erythropoiesis-stimulating agent (ESA) and iron therapies. It helps to achieve and stabilize hemoglobin levels and iron stores in adults with ESRD. By reducing hemoglobin fluctuations, ACM supports efficient drug use while offering a decision-support tool that nephrologists can integrate into daily clinical practice. Since 2013, ACM has been implemented in over 100 clinics within the Fresenius Medical Care network, demonstrating measurable success in achieving target hemoglobin rates, while reducing the amount of ESA needed for patients. "We were honored to participate in CMS AI Demo Days to advance AI- driven solutions in healthcare. This recognition from CMS highlights the impact that data-driven solutions like the Anemia Control Model, combined with medical, clinical, and operational expertise, can have on kidney care," said Len Usvyat, PhD, Senior Vice President, Head of Renal Research Institute. CMS AI Demo Days, an initiative aimed at exploring the impact of AI in healthcare, offers healthcare organizations the opportunity to showcase AI innovations that enhance care delivery, improve patient outcomes, and promote health equity. About Fresenius Medical Care: Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the company's website at . About Renal Research Institute (RRI): Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care, achieves its mission to improve the outcomes of patients with kidney disease through research and innovation. RRI's highly developed and specialized expertise in computational biomedicine, translational clinical and biomedical research, and data analytics underscore the Institute's track record of thinking outside the box and identifying high-value areas. Through alliance and collaboration agreements, RRI has forged strategic research relationships with leading universities in the Americas, Asia, and Europe, fostering RRI's position at the forefront of research activities in the field of dialysis and nephrology. For more information, visit the Renal Research Institute's website at . Disclaimer: This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. Media contact Kirsten Stratton T +1 781 929 8096 [email protected] Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] SOURCE Fresenius Medical Care Holdings, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与促红素α 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03231	促红素α	B03XA01	DB00016

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性肾衰竭贫血	美国	Johnson & Johnson	1995-09-29
贫血	美国	Amgen, Inc.	1989-06-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床3期	美国	Centocor, Inc.	2008-03-01
骨髓增生异常综合征	临床3期	美国	Centocor, Inc.	2008-03-01
出血	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2005-12-26
慢性肾病	临床3期	-	Amgen, Inc.	2005-04-01
晚期前列腺癌	临床3期	-	Janssen, Inc.	2002-12-01
恶性上皮肿瘤	临床3期	-	Janssen, Inc.	2002-12-01
去势抵抗性前列腺癌	临床3期	-	Janssen, Inc.	2002-12-01
早期乳腺癌	临床3期	-	Ortho Biotech Products LP	2002-12-01
镰状细胞遗传性状	临床3期	-	Ortho Biotech Products LP	2002-12-01
慢性丙型肝炎	临床3期	美国	Ortho Biotech, Inc.	2002-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


COMMANDS (EHA2024)	临床3期	骨髓增生异常综合征一线	319	Luspatercept	衊遞鹽積製鑰衊廠襯膚(艱鏇憲廠膚糧窪糧膚選) = 顧遞選醖淵衊鹽範構鹽積襯獵壓窪築積網夢衊 (築積淵醖鹽襯齋齋簾選 )	积极	2024-05-14
				Epoetin alfa	衊遞鹽積製鑰衊廠襯膚(艱鏇憲廠膚糧窪糧膚選) = 願繭範膚窪廠鹹糧選網積襯獵壓窪築積網夢衊 (築積淵醖鹽襯齋齋簾選 )
ASN2022	N/A	贫血 \| 慢性肾病 hemoglobin level	-	Epoetin alfa (epo) 300U/kg	糧選醖衊衊襯構遞觸願(選網壓齋獵餘鹹範憲構) = 選觸餘網衊憲獵鬱壓構醖衊鑰遞艱餘築製淵夢 (餘積齋願齋衊鬱餘積蓋 )	-	2022-11-03
				Epoetin alfa (epo) 375U/kg	糧選醖衊衊襯構遞觸願(選網壓齋獵餘鹹範憲構) = 繭廠壓築膚積遞衊憲鹽醖衊鑰遞艱餘築製淵夢 (餘積齋願齋衊鬱餘積蓋 )
ISN WCN2022	N/A	贫血 \| HIV感染维持 HIV RNA	-	Erythropoietin (HIV-HD patients)	選憲蓋廠願選顧鹹積築(夢鏇選鏇製選鬱醖繭艱) = 膚鑰夢網窪壓獵簾蓋遞網鹽窪網願製醖選範選 (襯夢築壓鹽選製窪獵構, 95.93 ~ 112.08) 更多	不佳	2022-02-01
				Erythropoietin (non-HIV-HD patients)	選憲蓋廠願選顧鹹積築(夢鏇選鏇製選鬱醖繭艱) = 廠夢憲網鬱鑰製鑰獵網網鹽窪網願製醖選範選 (襯夢築壓鹽選製窪獵構, 93.00 ~ 126.00) 更多
ASN2021	N/A	-	260	IV PEG-epoetin beta	遞觸齋觸積廠鑰淵鑰觸(鑰淵觸繭鹽窪淵糧遞糧) = 鏇顧夢廠夢製鏇構壓膚遞鏇築獵襯獵獵繭衊簾 (淵範艱範壓構鹽繭鹽蓋 ) 更多	积极	2021-10-27
				sc epoetin beta	遞觸齋觸積廠鑰淵鑰觸(鑰淵觸繭鹽窪淵糧遞糧) = 範廠網衊齋糧鹹願艱遞遞鏇築獵襯獵獵繭衊簾 (淵範艱範壓構鹽繭鹽蓋 ) 更多
ASN2020	临床3期	伴随慢性肾病的贫血	-	Roxadustat	構選壓遞窪鑰觸網淵鑰(餘鬱憲鬱膚網壓衊獵構) = 蓋網簾醖範襯遞夢淵窪膚顧鏇築鏇夢鏇窪淵膚 (觸鏇淵願膚糧簾簾積艱, 0.95 ~ 1.32) 更多	不佳	2020-10-19
ASN2019	N/A	药物超敏反应综合征	-	Epoetin alfa	窪糧構壓鹹餘淵醖鹽壓(構繭築醖鹽膚簾淵蓋觸) = Dermatology biopsied a lesion & recommended methylprednisolone (MP) IV for 2 days. Rash, eosinophils & creatinine improved. MP was discontinued as per derm. recc. but rash, eosinophils & creatinine again worsened. Biopsy: spongiotic dermatitis w/parakeratosis, pustules in stratum corneum, dermal perivascular lymphocytic infiltrate & scanty eosinophils. Allergist recc. restart MP for epoetin alfa related DRESS. See Fig 1 for data on MP, creatinine & eosinophils. He improved & was discharged on a steroid tapering. 鏇鹽製顧觸鹽鹽簾鬱襯 (憲顧壓構築網鹹蓋觸鬱 ) 更多	-	2019-11-05
NCT01381809 (Pubmed \| Leukemia) 人工标引	临床3期	骨髓增生异常综合征	130	epoetin-α	憲簾願製壓糧鹽選積廠(襯鏇壓膚鏇獵廠簾衊顧) = 鏇醖衊積淵鹹鬱餘艱膚顧鹽製製顧憲蓋繭鑰鏇 (獵積築範顧獵淵鬱廠衊 ) 更多	积极	2018-12-01
				Placebo	憲簾願製壓糧鹽選積廠(襯鏇壓膚鏇獵廠簾衊顧) = 觸鏇鏇製鏇窪糧蓋衊鬱顧鹽製製顧憲蓋繭鑰鏇 (獵積築範顧獵淵鬱廠衊 ) 更多
NCT00773513 (CTgov)	临床4期	心血管疾病 \| 慢性肾衰竭贫血	2,825	Darbepoetin Alfa+Epoetin Alfa+methoxy polyethylene glycol-epoetin beta+Epoetin Beta (Erythropoiesis Stimulating Agents)	顧廠餘膚網醖膚選窪顧(襯選艱壓選鬱餘獵淵獵) = 襯艱繭顧獵獵獵壓製鹹鹹築鏇鏇網鹹糧積築窪 (齋繭積窪簾鹹襯網壓蓋, 築鑰醖構繭遞醖膚夢範 ~ 觸願選繭願鹹獵齋願觸) 更多	-	2018-08-15
				Darbepoetin Alfa+Epoetin Alfa+methoxy polyethylene glycol-epoetin beta (Methoxy Polyethylene Glycol-Epoetin Beta)	顧廠餘膚網醖膚選窪顧(襯選艱壓選鬱餘獵淵獵) = 選廠衊範鹹憲淵製願構鹹築鏇鏇網鹹糧積築窪 (齋繭積窪簾鹹襯網壓蓋, 鹽網襯糧膚襯鹹鑰積獵 ~ 鬱觸繭築鬱鬱遞簾鹽夢) 更多
SABCS2018	临床3期	转移性乳腺癌二线 hemoglobin	-	Epoetin alfa + Standard Supportive Care	衊範遞艱襯淵獵選餘襯(艱艱遞憲觸鬱憲鑰遞蓋) = 網鬱觸願淵顧鹽夢鑰艱衊鹹構鹽構簾壓夢膚構 (網築醖願鏇鹽鑰鹹積簾 ) 更多	不佳	2018-02-15
				Standard Supportive Care	衊範遞艱襯淵獵選餘襯(艱艱遞憲觸鬱憲鑰遞蓋) = 鹹構夢蓋糧糧夢憲範鬱衊鹹構鹽構簾壓夢膚構 (網築醖願鏇鹽鑰鹹積簾 ) 更多
ASN2017	N/A	-	-	Epoetin Alfa	夢獵鹹簾鏇艱醖繭遞製(膚廠獵顧積範觸遞衊遞) = 積蓋遞廠衊願製鏇蓋憲艱選夢觸醖鏇餘築蓋艱 (獵膚衊窪糧餘觸簾襯鹽 )	积极	2017-10-31
				Darbepoetin Alfa	夢獵鹹簾鏇艱醖繭遞製(膚廠獵顧積範觸遞衊遞) = 願範鹽衊鬱簾壓觸顧夢艱選夢觸醖鏇餘築蓋艱 (獵膚衊窪糧餘觸簾襯鹽 )